Champions Oncology, Inc.
CSBR · NASDAQ
10/31/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.49 | 0.66 | 0.10 | 0.02 |
| FCF Yield | -2.10% | 0.64% | 6.73% | 0.30% |
| EV / EBITDA | 148.84 | -878.38 | -60.29 | 31.29 |
| Quality | ||||
| ROIC | 1.80% | -5.42% | -16.08% | 36.72% |
| Gross Margin | 49.32% | 40.31% | 37.96% | 58.83% |
| Cash Conversion Ratio | -7.35 | -1.29 | -3.74 | 0.11 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.34% | 2.58% | 1.87% | 2.96% |
| Free Cash Flow Growth | -456.86% | -91.63% | 1,376.56% | 218.83% |
| Safety | ||||
| Net Debt / EBITDA | -5.31 | 48.67 | 2.34 | 0.66 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1.72 | 8.72 | 31.96 | 18.02 |